Paris, France, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Meiogenix, an agriculture biotech company using the process of Chromosome Editing to expand genetic diversity in food and agriculture, announced today the closing of a $13 million (€11 million) Series A financing round, led by Sofinnova Partners, with participation from Genoa Ventures, Bpifrance, Casdin Capital and Alexandria Venture Investments.
"We're at an exciting stage of our development," said Luc Mathis, CEO of Meiogenix. "The Series A funding will provide capital for our implementation in the United States and further product development. The caliber of our global investor syndicate reflects our international expansion strategy to pursue innovation in Europe and focus product development in North America."
Meiogenix has developed an innovative approach to common problems in agriculture, addressing key global food and industrial challenges. Meiogenix is applying gene and chromosome editing technologies to accelerate nature's generation of biodiversity through the mixing of parental genomes during plant reproduction. This helps expedite the lengthy process of plant varieties selection and also leads to increased biodiversity, lost during the systematic selection of crops for high yield and long shelf life. The ability to restore a plant's immunity to pests and diseases, and improve quality, taste and flavor in many crops also has the potential to revolutionize the AgriFood Tech sector. Key benefits of the platform include more access to natural food products for customers and less chemicals required in growing food.
"This investment reflects our expanding interest in the application of biotech in agriculture," said Michael Krel, Partner at Sofinnova Partners, and a key member of the Sofinnova Industrial Biotech Funds. "Meiogenix has the potential to revolutionize the way we enhance the natural properties of plants so that they are more resistant to viruses, better tasting, and produce higher yield. We are confident in this team's ability to bring its groundbreaking science to significantly improve the safety and sustainability of our global food systems."
The Meiogenix platform addresses the $50 billion commercial seed market and breeding capabilities of large and essential crops like corn, wheat, rice, soybeans and tomatoes.
"Our investment in Meiogenix is based on their unique approach to solving critical bottlenecks in food production for the commercial seed industry, a rapidly growing market expected to surpass $60 billion by 2025," said Jenny Rooke, Ph.D., Founder and Managing Director of Genoa Ventures. "The agriculture industry is ripe for translating great innovations in life sciences to agricultural applications, and leaders in the space are investing heavily in the latest gene editing technologies to accelerate improved product development. Meiogenix's relationships with innovative industry leaders like Bayer further demonstrate the enormous potential for the Meiogenix platform to usher in the next stage of progress for the agricultural industry."
Meiogenix is a pioneer in chromosome editing, developing broadly applicable gene and chromosome editing capabilities that restore essential biodiversity to agriculture, enabling unity between natural ecosystems and our food production. Meiogenix has collaborations with Cornell and Bayer to help develop crops that improve our food supply while caring for our environment. For more information, see www.meiogenix.com or contact us at: email@example.com
CinCor Pharma announces positive topline data for Phase 2 BrigHtn trial evaluating baxdrostat, its selective aldosterone synthase inhibitor, in treatment-resistant hypertension
F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim
Noema Pharma announces recruitment of first patient in Orpheus Phase 2b Study of PDE10A inhibitor gemlapodect in adults with childhood onset fluency disorder
CinCor Pharma announces last patient randomized in Phase 2 HALO Trial and initiation of long-term extension study for Baxdrostat, a selective aldosterone synthase inhibitor, in uncontrolled hypertension
ReCor Medical and Otsuka Medical Devices announce primary endpoint met in the RADIANCE II U.S. pivotal trial of the Paradise™ System for the treatment of hypertension